Sign up
Pharma Capital

NetScientific portfolio company Vortex enters manufacturing partnership with STRATEC

The firm said STRATEC would assist Vortex in producing a customised chip, a crucial component of its VTX-1 liquid biopsy platform
Scientist
The agreement is also aimed at increasing VTX-1's prominence in the clinical space

NetScientific PLC’s (LON:NSCI) portfolio company, Vortex BioSciences, has secured a global manufacturing agreement with German firm STRATEC Consumables GmbH to scale up production of its VTX-1 liquid biopsy platform.

The healthcare IP commercialisation firm said STRATEC would assist Vortex in producing a customised chip, a crucial component of its automated platform, as well as assisting the company with scaling up to commercial viability and increasing the product’s prominence in the clinical space as a diagnostic and monitoring tool.

WATCH: 'Pivotal' moment for NetScientific's Glycotest Inc with $10mln financing

Francois Martelet, chief executive of NetScientific and chairman of Vortex, said the partnership would help create a reproducible process that would “allow Vortex's technology to enter the market and readily address demand as it surges”.

NetScientific holds a 66.1% stake in Vortex.

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.